Biogen Stock News

Biogen Inc. (BIIB) closed at $193.77 in the latest trading session, marking a -1.97% move from the prior day.

Biogen Inc (NASDAQ: BIIB ) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and NURTURE studies. The first patient treated in the ASCEND study is evaluating the higher dose nusinersen in children, teens, and adults previously treated with Roche Holdings AG''s (OTC: RHHBY ) Evrysdi (risdiplam). ASCEND aims to Full story available on Benzinga.com

New data found that infants with spinal muscular atrophy treated in the presymptomatic phase with Biogen (BIIB) Spinraza (nusinersen) led to progressive gains in motor function.

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research pro

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA ® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies. These updates will be presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13-16, 2022).

The patient advocacy groups in the U.S. have stepped up their efforts for a favorable decision on the coverage of Aduhelm and similar Alzheimer’s drugs as the developers await a…

By Deena Beasley (Reuters) – Patient groups are mounting a public pressure campaign aimed at persuading the U.S. government to loosen proposed restrictions on new Alzheimer’s treatments, spending millions of dollars on television and local advertisements that began running during the Sunday morning political shows.

Patient groups are spending millions of dollars on television and local advertisements targeting U.S. Sunday morning political talk shows.

Dallas, March 11, 2022 (GLOBE NEWSWIRE) -- As per the report published by The Brainy Insights, the global inflammatory bowel disease treatment market is expected to grow from USD 18.47 billion in 2020 to USD 28.96 billion by 2030, at a CAGR of 4.6% during the forecast period 2021-2030. Inflammatory bowel disease (IBD) is a term for illnesses involving chronic inflammation of the digestive tract. Some common symptoms of IBD are: abdominal pain, weight loss, persistent diarrhea, rectal bleeding and fatigue. Ulcerative colitis and Crohn''s disease are the two most common kinds of IBD. The colon or large intestine are the only parts of the body affected by ulcerative colitis. On the other hand, Crohn''s disease can affect any portion of the gastrointestinal tract, from the mouth to the anus. The last part of the small intestine or the colon, or both, are the most usually affected areas. Anti-inflammatory drugs are frequently used as the first line of treatment against inflammatory bowel disease.

CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM® (aducanumab-avwa

CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB ) announced the company will present new Alzheimer''s disease research, as well as data for ADUHELM ® (aducanumab-avwa) injection 100 mg/mL for intravenous use, at the upcoming International Conference on Alzheimer''s and Parkinson''s Diseases (AD/PD 2022), taking place March 15-20 in Barcelona, Spain and virtually. These data include analyses of treatment effect on biomarkers of Alzheimer''s disease in the long-term extension studies, with over two years of Phase 3 data. An invited plenary lecture, "Key Milestones in Alzheimer''s Disease" on March 16, will include an examination of the ability of ADUHELM to reduce amyloid beta plaque and plasma p-tau181, and the relationship between these biomarkers and clinical endpoints during the long-term extension phase of the ADUHELM clinical program. An oral presentation on March 18, "Effect of Reduction in Brain β-Amyloid Levels on Cognitive Decline in Randomized Clinical Trials: An Updated Instrumental Variable Meta-Analysis," will discuss the details of a meta-analysis on the causality between reduction of amyloid beta levels and reduction of cognitive decline in randomized clinical trials.

CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present new Alzheimer's disease research, as well as data for ADUHELM® (aducanumab-avwa) in

In the latest trading session, Biogen Inc. (BIIB) closed at $198.64, marking a -1.79% move from the previous day.

Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.

Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tumor program to initiate in H1 2022; preliminary data expected in H2 2022 Two INDs for TSC-200 series anticipated by year end Strong balance sheet with cash and cash equivalents of $161.4 million as of December 31, 2021; funds Company into 2024 WALTHAM, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ: TCRX ), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the full year ended December 31, 2021, and outlined key 2022 priorities. "As we had guided throughout 2021, in December we filed two INDs for our liquid tumor program. We also completed construction of our now fully functional 7,000 square-foot GMP manufacturing facility. Both of these steps are instrumental in our transformation to a clinical-stage company," said David Southwell, President and Chief Executive Officer. "We also advanced our growing pipeline of solid tumor candidates and look forward to sharing further details around these programs in the coming months." Recent Corporate Highlights In January 2022, the Company announced that the U.S.